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Abstract: 
Lysergic acid diethylamide (LSD) is perhaps one of the best-known 
psychoactive substances and many structural modifications of this 
prototypical lysergamide have been investigated. Several lysergamides 
were recently encountered as “research chemicals” or new psychoactive 
substances (NPS). Although lysergic acid morpholide (LSM-775) appeared 
on the NPS market in 2013, there is disagreement in the literature 
regarding the potency and psychoactive properties of LSM-775 in humans. 
The present investigation attempts to address the gap of information that 
exists regarding the analytical profile and pharmacological effects of LSM-
775. A powdered sample of LSM-775 was characterized by X-ray 
crystallography, nuclear magnetic resonance stereoscopy (NMR), gas 
chromatography mass spectrometry (GC-MS), high mass accuracy 
electrospray MS/MS, HPLC diode array detection, HPLC quadrupole MS, and 
GC solid-state infrared analysis. Screening for receptor affinity and 
functional efficacy revealed that LSM-775 acts as a nonselective agonist at 
5-HT1A and 5-HT2A receptors. Head twitch studies were conducted in 
C57BL/6J mice to determine whether LSM-775 activates 5-HT2A receptors 
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and produces hallucinogen-like effects in vivo. LSM-775 did not induce the 
head twitch response unless 5-HT1A receptors were blocked by 
pretreatment with the antagonist WAY-100,635 (1 mg/kg, 
subcutaneous).  These findings suggest that 5-HT1A activation by LSM-775 
masks its ability to induce the head twitch response, which is potentially 
consistent with reports in the literature indicating that LSM-775 is only 
capable of producing weak LSD-like effects in humans.   
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Abstract 
 
Lysergic acid diethylamide (LSD) is perhaps one of the best-known psychoactive 
substances and many structural modifications of this prototypical lysergamide have 
been investigated. Several lysergamides were recently encountered as “research 
chemicals” or new psychoactive substances (NPS). Although lysergic acid 
morpholide (LSM-775) appeared on the NPS market in 2013, there is disagreement 
in the literature regarding the potency and psychoactive properties of LSM-775 in 
humans. The present investigation attempts to address the gap of information that 
exists regarding the analytical profile and pharmacological effects of LSM-775. A 
powdered sample of LSM-775 was characterized by X-ray crystallography, nuclear 
magnetic resonance stereoscopy (NMR), gas chromatography mass spectrometry 
(GC-MS), high mass accuracy electrospray MS/MS, HPLC diode array detection, 
HPLC quadrupole MS, and GC solid-state infrared analysis. Screening for receptor 
affinity and functional efficacy revealed that LSM-775 acts as a nonselective agonist 
at 5-HT1A and 5-HT2A receptors. Head twitch studies were conducted in C57BL/6J 
mice to determine whether LSM-775 activates 5-HT2A receptors and produces 
hallucinogen-like effects in vivo. LSM-775 did not induce the head twitch response 
unless 5-HT1A receptors were blocked by pretreatment with the antagonist WAY-
100,635 (1 mg/kg, subcutaneous).  These findings suggest that 5-HT1A activation by 
LSM-775 masks its ability to induce the head twitch response, which is potentially 
consistent with reports in the literature indicating that LSM-775 is only capable of 
producing weak LSD-like effects in humans.   
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Introduction 
 
The hallucinogenic properties of lysergic acid diethylamide (LSD; Figure 1) and other 
lysergamides have been investigated extensively.[1-7] Although most of the recent 
research with lysergamides has focused on their pharmacology and structure-activity 
relationships,[8-11] studies have also assessed potential therapeutic applications.[12,13] 
LSD is a popular recreational drug and its use has remained relatively stable over the 
past few decades. Recently, however, other lysergamides have been distributed as 
“research chemicals” or new psychoactive substances (NPS),[14] including 1-
propionyl-LSD (1P-LSD),[15] N6-allyl-6-norlysergic acid diethylamide (AL-LAD),[16] 
(2′S,4′S)-lysergic acid 2,4-dimethylazetidide (LSZ),[16] N6-ethyl-6-norlysergic acid 
diethylamide (ETH-LAD),[17] and 1-propionyl-ETH-LAD (1P-ETH-LAD).[17] These 
lysergamides are shown in Figure 1. Lysergic acid morpholide (LSM-775) appeared 
as an NPS in 2013, presumably based on reports from the late 1950s indicating that 
it may have LSD-like effects in humans.  
 
The preparation of LSM-775 was first described in the 1950s by Stoll and 
Hoffmann[18] and several other routes have also been reported.[19-21] There is 
disagreement in the literature regarding the potency and psychoactive properties of 
LSM-775 in humans. Goggerty and Dille reported that 75 µg LSM-775 produced 
approximately the same response as 50 µg LSD in two subjects, although LSM-775 
had a shorter duration of action than LSD.[22] In a blinded experiment conducted by 
Abramson, two subjects administered 150 µg LSM-775 estimated that they had 
received 25‒35 µg LSD, whereas a third subject estimated that they had received a 
placebo.[23] Isbell et al. found that higher doses of LSM-775 (4.5 and 9 µg/kg) 
produced effects roughly equivalent to a threshold dose of LSD, but with a shorter 
duration.[24,25] One potential explanation for these discrepant findings is that LSM-775 
may be capable of producing only a threshold psychedelic response. However, the 
methodological weaknesses in early human studies with LSM-775 make 
interpretation challenging.  
 
The present investigation aimed to fill the gap of information that exists on the 
analytical profile and pharmacological effects of LSM-775. A powdered sample of 
LSM-775 was characterized by X-ray crystallography, nuclear magnetic resonance 
stereoscopy (NMR), gas chromatography mass spectrometry (GC-MS), high mass 
accuracy electrospray MS/MS, HPLC diode array detection, HPLC quadrupole MS, 
and GC solid-state infrared analysis.  
 
LSD and other lysergamide hallucinogens act as nonselective serotonin (5-HT) 
receptor agonists.  Although the characteristic effects of serotonergic hallucinogens 
are thought to be mediated by the 5-HT2A receptor,
[26-29] there is evidence indicating 
that the 5-HT1A receptor may also contribute to or modulate their effects.
[4,30] 
Interactions of LSM-775 with 5-HT1A and 5-HT2 receptor subtypes were assessed 
using competitive binding and functional assays.  
 
Serotonergic hallucinogens induce the head twitch response (HTR) in rodents due to 
5-HT2A receptor activation.
[31,32] The HTR is widely used as a behavioral proxy in 
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rodents for human hallucinogenic effects because it is one of the few behaviors that 
can reliably distinguish hallucinogenic and non-hallucinogenic 5-HT2A receptor 
agonists.[33] HTR studies were conducted in C57BL/6J mice to determine whether 
LSM-775 produces 5-HT2A receptor activation and LSD-like behavioral effects in vivo.   
 
Experimental 
 
Materials 
 
All chemicals used were of analytical or HPLC grade and were obtained from 
Rathburn Chemicals Ltd (Walkerburn, Scotland, UK), Fisher Scientific (Dublin, 
Ireland) or Aldrich (Dorset, UK). LSM-775 hemitartrate was obtained from Synex 
Synthetics BV (Delft, The Netherlands). LSM-775 tartrate from Lipomed Inc. 
(Cambridge, MA, USA) was used in the in vitro pharmacological studies.  N-[2-[4-(2-
Methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinylcyclohexanecarboxamide (WAY-
100,635) dihydrochloride was donated by Wyeth-Ayerst Research (Princeton, NJ, 
USA). 
 
Instrumentation  
 
Nuclear magnetic resonance spectroscopy  
The hemitartrate sample was prepared in deuterated dimethyl sulfoxide (DMSO-d6). 
1H (600 MHz) and 13C (150 MHz) spectra were recorded on a Bruker AV600 NMR 
spectrometer using a 5 mm TCI cryoprobe. 1
1
H NMR spectra were referenced to 
residual solvent at δ = 2.51 ppm and assignments were supported by both 1D and 
2D experiments.   
 
Gas chromatography mass spectrometry  
 
A Finnigan TSQ 7000 triple stage quadrupole mass spectrometer coupled to a gas 
chromatograph (Trace GC Ultra, Thermo Electron, Dreieich, Germany) was used to 
record electron ionization (EI) mass spectra (70 eV) and a CTC CombiPAL (CTC 
Analytics, Zwingen, Switzerland) autosampler was employed for sample introduction. 
The ion source temperature was set at 175°C and the emission current was 200 µA. 
The scan time was 1 s spanning a scan range between m/z 29–m/z 600 and 
samples were injected in splitless mode. Separation was achieved using a fused 
silica capillary DB-1 column (30 m × 0.25 mm, film thickness 0.25 µm). The 
temperature program consisted of an initial temperature of 80°C, held for 1 min, 
followed by a ramp to 310°C at 20 °C/min. The final temperature was held for 23 min. 
The injector temperature was 250°C. The transfer line temperature was set at 300 °C 
and the carrier gas was helium in constant flow mode at a flow rate of 1.0 mL/min. 
Approximately 2 mg were dissolved in 1.5 mL chloroform. For analysis, 1 µL sample 
solution was injected into the GC-MS system. Retention indices are given as Kovats 
indices calculated from measurement of a n-alkane mixture analyzed with the above 
mentioned temperature program. 
 
Gas chromatography solid-state infrared analysis 
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Samples were analyzed using a GC-solid phase-IR-system that consisted of an 
Agilent GC 7890B (Waldbronn, Germany) with probe sampler Agilent G4567A and a 
DiscovIR-GC™ (Spectra Analysis, Marlborough, MA, USA). The column eluent was 
cryogenically accumulated on a spirally rotating ZnSe disk cooled by liquid nitrogen. 
IR spectra were recorded through the IR-transparent ZnSe disk using a nitrogen-
cooled MCT detector. GC parameters: injection in splitless mode with an injection 
port temperature set at 240°C and a DB-1 fused silica capillary column (30 m × 
0.32 mm i.d., 0.25 µm film thickness). The carrier gas was helium with a flow rate of 
2.5 mL/min and the oven temperature program was as follows: 80°C for 2 min, 
ramped to 290°C at 20 °C/min, and held at for 20 min. The transfer line was heated 
at 280°C. Infrared conditions: oven temperature, restrictor temperature, disc 
temperature, and Dewar cap temperatures were 280°C, 280°C, -40°C, and 35°C, 
respectively. The vacuum was 0.2 mTorr, disc speed 3 mm/s, spiral separation was 1 
mm, wavelength resolution 4 cm-1 and IR range 650–4000 cm-1. Acquisition time was 
0.6 s/file with 64 scans/spectrum. Data were processed using GRAMS/AI Ver. 9.1 
(Grams Spectroscopy Software Suite, Thermo Fischer Scientific, Dreieich, Germany) 
followed by implementation of the OMNIC Software, Ver. 7.4.127 (Thermo Electron 
Corporation, Dreieich, Germany). 
 
High mass accuracy electrospray mass spectrometry  
Ultrahigh-performance liquid chromatography quadrupole time-of-flight single and 
tandem mass spectrometry (UHPLC-QTOF-MS/MS) data were obtained from an 
Agilent 6540 UHD Accurate-Mass Q-TOF LC-MS system coupled to an Agilent 1290 
Infinity UHPLC system (Agilent, Cheshire, UK). Separation was achieved using an 
Agilent Zorbax Eclipse Plus C18 column (100 mm × 2.1 mm, 1.8 µm) (Agilent, 
Cheadle, UK). Mobile phases consisted of acetonitrile (1% formic acid) and 1% 
formic acid in water. The column temperature was set at 40°C (0.6 mL/min) and data 
were acquired for 5.5 min. The gradient was set at 5–70% acetonitrile over 3.5 min, 
then increased to 95% acetonitrile in 1 min and held for 0.5 min before returning to 
5% acetonitrile in 0.5 min. QTOF-MS data were acquired in positive mode scanning 
from m/z 100–m/z 1000 with and without auto MS/MS fragmentation. Ionization was 
achieved with an Agilent JetStream electrospray source and infused internal 
reference masses. QTOF-MS parameters: gas temperature 325°C, drying gas 10 
L/min and sheath gas temperature 400°C. Internal reference ions at m/z 121.05087 
and m/z 922.00979 were used for calibration purposes.   
 
Liquid chromatography diode array detection 
 
A Dionex 3000 Ultimate liquid chromatography system coupled to a UV diode array 
detector (Thermo Fisher, St. Albans, UK) was used for analysis using a Phenomenex 
Synergi Fusion column (150 mm × 2mm, 4 µm) that was protected by a 4 mm × 3 
mm Phenomenex Synergi Fusion guard column (Phenomenex, Cheshire, UK). The 
Mobile phases were 70% acetonitrile with 25 mM of triethylammonium phosphate 
buffer (TEAP) (B) and aqueous TEAP (25 mM) buffer (A). The gradient elution 
commenced with 4% B and ramped to 70% B in 15 min and held for 3 min, resulting 
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in a total acquisition time of 18 min at a flow rate of 0.6 mL/min. The diode array 
detection window was set at 200 nm–595 nm (collection rate 2 Hz).  
 
Liquid chromatography electrospray mass spectrometry 
 
Analyses were carried on an Agilent 1100 system using a Restek (Bellefonte, PA, 
USA) Allure PFPP column (5 µm, 50 × 2.1 mm). The aqueous mobile phase A 
consisted of 0.1% formic acid, whereas, mobile phase B consisted of 0.1% formic 
acid in acetonitrile. The total run time was 25 min. The following gradient elution 
program was used: 0–2 min 2% B, followed by an increase to 60% within 15 min, 
then up to 80% within 20 min, returning to 2% within 25 min. The Agilent LC-MSD 
settings were as follows: positive electrospray mode, capillary voltage 3500 V, drying 
gas (N2) 12 L/min at 350°C, nebulizer gas (N2) pressure 50 psi, Scan mode m/z 70–
500, fragmentor voltage values used for in-source collision-induced dissociation 
(CID) were 30 V and 150 V, respectively. The sample was dissolved in 
acetonitrile/water (1:1, containing 0.1% formic acid) at a concentration of 10 µg/mL. 
The injection volume was 1 µL, flow rate was 0.80 mL/min and the column 
temperature was 30°C.  
 
X-ray crystallography 
Data for LSM-775 were collected on a Bruker APEX DUO with Cu Kα radiation (λ = 
1.54184 Å) using a MiTeGen micromount and at 100(2) K (Oxford Cobra 
Cryosystem). Bruker APEX2 software[34] was used to collect and reduce data, 
determine the space group, solve and refine the structure. Absorption corrections 
were applied using SADABS.[35,36] All final refinements were performed with XL.[37] All 
non-hydrogen atoms were refined anisotropically and all donor hydrogen atoms were 
located and refined with restraints. All other hydrogen atoms were assigned to 
calculated positions using a riding model. The ethanol solvent molecule C-C bond 
was restrained (DFIX). Absolute configuration was established by anomalous-
dispersion effects in diffraction measurements on the crystal. Cambridge 
Crystallographic Dater Centre (CCDC) 1486037 contains the supplementary 
crystallographic data. Crystal data and structure refinement parameters were as 
follows: C46H60N6O12, M = 889.0, T = 100(2) K, orthorhombic, P212121, a = 5.9621(2), 
b = 15.5087(6), c = 47.4811(19) Å, V = 4390.3(3) Å3, Z = 4, µ (Cu Kα) = 0.807 mm−1, 
ρ = 1.345 Mg/cm3, 57701 reflections collected, 8027 independent (Rint = 0.0444), 
aR1 
= 0.0371, wR2 = 0.0979 (I > 2σ(I)), S = 1.050. CCDC 1486037. aR1 = Σ||Fo| − 
|Fc||/Σ|Fo|, wR2 = [Σw(Fo
2 − Fc
2)2/Σw(Fo
2)2]1/2. 
 
Pharmacological Experiments 
 
Head-twitch response 
 
Male C57BL/6J mice (6−8 weeks old) were obtained from Jackson Laboratories (Bar 
Harbor, ME, USA) and housed up to four per cage on a reversed light-cycle (lights on 
at 1900 h, off at 0700 h). Food and water were provided ad libitum, except during 
behavioral testing, which was performed between 1000 h and 1800 h. The head 
twitch response (HTR) was detected using a head mounted magnet and a 
Page 7 of 29
http://mc.manuscriptcentral.com/dta
Drug Testing and Analysis
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 7
magnetometer coil, as described previously.[32,38] In experiment 1, mice (n = 6/group, 
30 total) were treated with vehicle or LSM-775 (0.1, 0.3, 1, or 3 mg/kg).  In 
experiment 2, mice (n = 6/group, 30 total) were pretreated with 1 mg/kg WAY-
100,635 20 min prior to treatment with vehicle or LSM-775 (0.1, 0.3, 1, or 3 mg/kg).  
In experiment 3, mice (n = 5–6/group, 23 total) were pretreated with vehicle or 1 
mg/kg WAY-100,635 20 min prior to treatment with vehicle or 1 mg/kg LSM-775.  
Behavior was monitored for 30 min immediately after treatment with LSM-775. LSM-
775 was dissolved in isotonic saline and injected intraperitoneally (IP) (5 mL/kg); 
WAY-100,635 was dissolved in sterile water and injected subcutaneously (SC) (5 
mL/kg). HTR counts were analyzed by one-way or two-way ANOVAs; post-hoc 
comparisons were made using Tukey’s studentized range method. Significance was 
demonstrated by surpassing an α-level of 0.05.  ED50 values and 95% confidence 
intervals were calculated using nonlinear regression. 
 
Binding studies 
 
Radioligand binding studies for human 5-HT1A and human 5-HT2A receptors were 
performed by the NIMH Psychoactive Drug Screening Program (NIMH PDSP). LSM-
775 was dissolved in DMSO and primary binding screens were conducted in 
quadruplicate. Sites exhibiting >50% inhibition at 10 µM were tested in competitive 
binding assays to determine Ki values. The experimental protocols are available from 
the NIMH PDSP website.[39]  
 
5-HT2 receptor functional assays 
 
5-HT2 functional experiments (measuring Gq-mediated calcium flux) were performed 
with Flp-In T-REx 293 cells (Invitrogen, Carlsbad, CA, USA) expressing either human 
5-HT2A, mouse 5-HT2A, human 5-HT2B or human 5-HT2C INI receptor. The day before 
the assay, receptor expression was induced with 2 µg/mL tetracycline, and cells were 
plated into white 384 clear-bottom, tissue culture plates in 40 µL of DMEM containing 
1% dialyzed fetal bovine serum (FBS) at a density of approximately 15,000 cells per 
well. The next day, drug dilutions were diluted in drug buffer (HBSS, 20 mM HEPES, 
0.1% BSA, 0.01% ascorbic acid, pH 7.4). Before the assay, media was decanted and 
replaced with 20 µL per well of drug buffer (HBSS, 20 mM HEPES, pH 7.4) 
containing Fluo-4 Direct dye (Invitrogen) and incubated for 1 h at 37°C. Plates were 
allowed to equilibrate to room temperature and calcium flux was measured using a 
FLIPRTETRA (Molecular Devices, Sunnyvale, CA, USA). Plates were read for 
fluorescence initially for 10 seconds (1 read per second) to establish a baseline, and 
then stimulated with drug dilutions or buffer and read for an additional 110 seconds. 
Peak fluorescence in each well was normalized to maximum-fold increase over 
baseline. Data were normalized to the maximum peak fold-over-basal fluorescence 
produced by 5-HT (100%) and baseline fluorescence (0%). Data were analyzed 
using the sigmoidal dose-response function of GraphPad Prism 5.0.  
 
5-HT1A receptor functional assays 
 
5-HT1A functional experiments (measuring Gi/o-mediated cAMP inhibition) were 
performed in HEK293T cells (ATCC, Manassas, VA, USA) co-expressing the 
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GloSensor cAMP biosensor (Promega, Madison, WI, USA) and the human 5-HT1A 
receptor. On the day of transfection, HEK cells were washed with PBS, and 10% 
dialyzed FBS in DMEM was added to cells before addition of calcium phosphate 
precipitation transfection mix containing a 1:1 ratio of GloSensor-22F and human 5-
HT1A receptor DNA. The next day, cells were plated into white 384 clear-bottom, 
tissue culture plates in 40 µL of DMEM containing 1% dialyzed FBS at a density of 
approximately 15,000 cells per well. On the day of the assay, drug dilutions prepared 
for 5-HT1A receptor functional assays were the same drug dilutions used for 5-HT2 
receptor functional assays, where the assays were performed in parallel on the same 
day. Before the assay, plate media was decanted and replaced with 20 µL per well of 
drug buffer (HBSS, 20 mM HEPES, pH 7.4) containing GloSensor substrate and 
allowed to equilibrate for at least 15 min at room temperature. To start the assay, 
cells were treated with 10 µL per well of drug using a FLIPR (Molecular Devices) and 
incubated for 15 min. Afterwards, cAMP accumulation was initiated by addition of 0.3 
µM isoproterenol (final concentration) and luminescence per well per second was 
counted 15 min later on a TriLux microbeta plate reader (PerkinElmer, Waltham, MA, 
USA). Data were normalized to the maximum cAMP inhibition produced by 5-HT 
(100%) and basal cAMP accumulation induced by isoproterenol (0%). Data were 
analyzed using the sigmoidal dose-response function of GraphPad Prism 5.0.  
 
Results and Discussion 
 
Analytical characterization 
 
Electron ionization (EI) mass spectra and Kovats indices for LSM-775 are displayed 
in Figure 2. As shown in the insert of Figure 2A, analysis by GC-MS revealed the 
detection of a second, minor peak that exhibited a similar mass spectrum, thus, 
indicating the potential presence of a diastereomer. Whether the presence of the 
extra peak was artificially induced by GC conditions, as reported previously for 
lysergic acid 2,4-dimethylazetidide (LSZ)[16] or whether it reflected a contaminant 
present in the powdered sample could not be established unambiguously. However, 
as shown below, a second peak was also detected under HPLC single quadrupole 
MS conditions (HPLC-Q-MS) using single ion monitoring (SIM), which suggested that 
the diastereomer may have been present in the sample. The EI mass spectrum 
associated with the major GC peak (Figure 2B, isomer II) reflected the identity of the 
correctly configured LSM-775. Suggested EI-MS fragmentation pathways for LSM-
775 have been provided as Supporting Information, which followed similar principles 
discussed previously for other lysergamides, such as 1P-LSD, AL-LAD, LSZ, ETH-
LAD, and 1P-ETH-LAD.[15-17] Fragments associated with LSM-775 specifically 
included m/z 337 (highly abundant molecular ion), m/z 294 (retro-Diels-Alder) and 
m/z 279. Ergoline-related fragments ions and fragment clusters that have also been 
observed with other lysergamides (e.g. m/z 151–m/z 154 or m/z 178–m/z 181)[15-17] 
were also detected (see the Supporting Information). Figure 3 provides the solid-
state infrared (IR) spectrum of the main LSM-775 isomer II following elution from the 
GC column. A key feature that differentiated LSM-775 from the lysergamides 
reported previously[15-17] was detected at 1115.6 cm-1, which may reflect the C-O 
stretch correlated with the morpholine ring. 
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UHPLC-ESI-QTOF-MS/MS, LC-Q-MS and LC-DAD data collected from LSM-775 are 
summarized in Figure 4. The proposed identity of the product ions under QTOF-
MS/MS conditions are summarized in the Supporting Information section and were 
based on the principles reported previously for other lysergamides.[15-17] Product ions 
characteristic for LSM-775, apart from the protonated molecule at m/z 338.18660 
(C20H24N3O2
+, 338.18630, ∆ = 0.89 ppm), included m/z 323.16165 (C19H21N3O2
•+, 
323.16283, ∆ = -3.65 ppm) and m/z 295.14449 (C18H19N2O2
+, 295.14410, ∆ = 1.32 
ppm) (see the Supporting Information). A product ion of minor abundance detected at 
m/z 114.05556 may represent the morpholine-4-carbonyl species (C5H8NO2
+, 
114.05495, ∆ = 5.35 ppm). In-source collision-induced dissociation spectra obtained 
from analysis by HPLC-Q-MS and increasing fragmentor voltages are shown in 
Figure 4B–4E. The sodiated adduct at m/z 360 was also detected. The most 
abundant product ions were detected at m/z 208, m/z 223, and m/z 295. HPLC-Q-
MS analysis in SIM mode also revealed a second peak at 9.039 min (LSM-775 
isomer 2) (Figure 4F), although it was not possible to determine whether this 
represented the 8α-epimer iso-LSM-775. The HPLC-DAD spectrum recorded for 
LSM-775 (Figure 4G) was essentially similar to that obtained with other 
lysergamides[15-17] and hence had limited value for differentiation under these 
conditions.  
 
Table 1 provides a summary of proposed identifications of chemical shifts obtained 
from analysis by nuclear magnetic resonance spectroscopy (NMR). Assignments 
were aided by two-dimensional experiments and comparison with lysergamides 
reported and discussed in detail previously using the same deuterated solvent (d6-
DMSO).[15-17] NMR spectra are provided as Supporting Information. Residual solvent 
traces, possibly tert-butanol and isopropanol,[40] were also detected in the 1H and 13C 
NMR spectra (Supporting Information). In the 13C NMR spectrum, the morpholine 
methylenes were detected as four separate resonances due to restricted rotation 
associated with the amide bond, although the methylene groups from the amide (C-
22) were only separated marginally by 0.18 ppm (see Table 1 and the Supporting 
Information). The remaining carbon chemical shifts were comparable to the 
lysergamides reported in earlier studies.[15,16]  
 
The morpholine ring protons could not be sufficiently resolved to determine the 
corresponding coupling constants or splitting patterns. The HSQC experiment 
suggested that the broad multiplet between 3.67–3.57 ppm represented overlapping 
contributions from the four NCH2 (2 x CH2-22) and one OCH2 (1 x CH2-21) protons. 
The other two CH2-21 methylene protons were detected slightly more upfield 
between 3.53–3.49 ppm and this multiplet overlapped with the resonance from the 
4β-proton, also visible in the HSQC experiment. The 4α-H proton overlapped with the 
N6-methyl group singlet (CH3-17), thus giving rise to the multiplet around 2.53–2.49 
ppm, which was observed previously with other lysergamides[15,16] (see the 
Supporting Information). The NMR data also revealed the presence of residual 
solvents (isopropanol and tert-butanol) that may have been used to recrystallize 
LSM-775 during the manufacturing process (Supporting Information). Some 
inaccuracies were encountered in the integration of the proton signals due to an 
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increasing baseline, but these were not subsequently observed when the NMR 
spectra were recorded again in a different solvent (CD3OD) (Supporting Information).  
 
Clear colorless needles of LSM-775 obtained by recrystallization with ethanol and 
water were used to determine the structure at 100 K. The data were solved and 
refined in the chiral orthorhombic space group P212121 and the absolute configuration 
was established. The asymmetric unit consists of two independent protonated 
cationic molecules of LSM-775 and a dianionic tartrate counter ion, as well as a 
water and an ethanol molecule (Figure 5A). The two LSM-775 molecules were 
similar except for a twist between the methylindoloquinoline and morpholine groups 
that exhibited the same chirality (R) at each center (see the Supporting Information 
for a detailed description of the conformational differences between the two LSM-775 
molecules). N11 and N36 on each molecule were protonated and formed hydrogen 
bonds to the dianionic tartrate molecule, with d(D-A) distances N11-O51 = 2.729(3)Å 
and N36-O59i4 = 2.631(3)Å (symmetry operation i4 = x, y+1, z). The water molecule 
also forms a hydrogen bond to the tartrate (O61-O60 = 2.831(3)Å), while the ethanol 
molecule forms a hydrogen bond to the water (O62-O61 = 2.795(4)Å). This 
solvent/anion unit formed a central scaffold around which three molecules of LSM-
775 were arranged: two as discussed above and another that hydrogen bonded via 
the N-H of the five-membered ring in the indoloquinoline (N21-O26i7 = 2.859(3)Å; 
N46-O53i5 = 2.908(3)Å; symm try operation i7 = x-1/2,-y+3/2,-z+2, i5 = -x,y+1/2,-
z+3/2) (Figure 5B).  
 
Pharmacology 
 
Interaction of LSM-775 with 5-HT1A and 5-HT2 receptors 
 
In vitro pharmacological studies were conducted in order to characterize the 
interaction of LSM-775 with 5-HT1A and 5-HT2 receptors.  The affinity of LSM-775 for 
recombinant human 5-HT1A and 5-HT2A receptors labeled with [
3H]8-OH-DPAT and 
[3H]ketanserin, respectively, was assessed in competitive binding assays. The Ki 
values are reported in Table 2.  LSM-775 has equivalent affinity for 5-HT1A (Ki = 31.0 
± 7.4 nM) and 5-HT2A (Ki = 29.5 ± 4.1 nM) receptors. 
 
The data from functional studies in cloned receptors are summarized in Table 3. 
LSM-775 inhibited cAMP accumulation in HEK293 cells expressing the human 5-
HT1A receptor and acted as a full agonist, with a 1 nM EC50. The effect of LSM-775 
on 5-HT2A, 5-HT2B, and 5-HT2C receptors was assessed using Gq-mediated Ca
2+ 
mobilization in HEK293 cells. LSM-775 was a partial agonist at all three 5-HT2 
receptor subtypes.  The potency of LSM-775 varied across the three subtypes, with 
LSM-775 having higher potency and efficacy at human 5-HT2A receptors (EC50 = 4.9 
nM; Emax = 89%) compared to 5-HT2B (EC50 = 26 nM; Emax = 77%) and 5-HT2C (EC50 
= 230 nM; Emax = 77%) receptors. The effect of LSM-775 on the mouse 5-HT2A 
receptor was also assessed; LSM-775 had similar efficacies at the human and 
mouse receptors but activated the human 5-HT2A receptor with almost 4-fold higher 
potency compared to the mouse receptor. 
 
Head-twitch response 
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Although there was a main effect of drug treatment (F(4,25)=5.45, p=0.0027), LSM-
775 alone did not significantly increase the HTR rate over baseline levels (Figure 6A).  
By contrast, as shown in Figure 6B, LSM-775 produced a robust increase in HTR 
frequency in animals pretreated with 1 mg/kg of the 5-HT1A antagonist WAY-100,635 
(F(4,25)=19.00, p<0.0001). In the presence of WAY-100,635, LSM-775 induced the 
HTR with an ED50 = 0.34 mg/kg (95% CI: 0.24-0.50 mg/kg). Similar to other 
lysergamides,[16] the response to LSM-775 followed an inverted-U-shaped dose-
response function, with the maximal effect occurring at 1 mg/kg.  
 
To confirm that the HTR induced by LSM-775 in the presence of WAY-100,635 is not 
due to additive effects between the two drugs, the interaction between 1 mg/kg WAY-
100,635 and 1 mg/kg LSM-775 was examined in a single experiment.  There was a 
significant interaction between WAY-100,635 and LSM-775 (F(1,19)=64.22, 
p<0.0001).  Although LSM-775 alone did not significantly increase HTR counts above 
baseline levels, LSM-775 induced the HTR in mice pretreated with WAY-100,635 
(p<0.0001, Tukey’s test; see Figure 7).  There was a main effect of pretreatment with 
WAY-100,635 (F(1,19)=79.63, p<0.0001), but WAY-100,635 failed to significantly 
increase HTR counts (6.3 ± 2.1 (mean ± SEM)) above the level observed in vehicle 
control mice (4.5 ± 0.8).  There was also a main effect of LSM-775 (F(1,19)=78.45, 
p<0.0001). 
 
According to several reports, blockade of 5-HT1A receptors with WAY-100,635 or (S)-
(–)-UH-301 induces the HTR in mice.[41-43] Importantly, however, 5-HT1A antagonists 
only induce the HTR during the light-phase of the light-dark cycle.[41] The present 
experiments confirmed that WAY-100,635 does not increase HTR counts when 
tested in mice during the dark-phase (Figure 7), which is an important finding 
because any effects of WAY-100,635 on baseline HTR expression would potentially 
confound interpretation of the interaction with LSM-775. 
 
In summary, LSM-775 does not induce the HTR in mice despite having moderately 
high affinity for 5-HT2A receptors and acting as an agonist.  For comparative purposes 
LSD binds to cloned human 5-HT2A receptors labeled with [
3H]ketanserin with a Ki of 
13 nM.[44] Nevertheless, LSM-775 does produce a robust behavioral response in 
animals pretreated with a 5-HT1A antagonist.  In addition to activating 5-HT2A 
receptors, LSM-775 is also a potent and highly efficacious 5-HT1A receptor agonist.  
Based on these findings, it appears that 5-HT1A activation by LSM-775 masks its 
ability to induce the HTR.   
 
There is substantial evidence that 5-HT1A receptor activation can block the HTR and 
other 5-HT2A-mediated behavioral effects. For example, 5-HT1A receptor agonists 
such as 8-OH-DPAT, ipsapirone, and buspirone suppress the HTR induced by 
hallucinogens in rats and mice.[45-47] In monkeys, 8-OH-DPAT and other 5-HT1A 
agonists have been shown to attenuate the discriminative stimulus effects of the 5-
HT2A agonist DOM.
[48]  Additionally, based on an isobolographic analysis, 5-HT1A and 
5-HT2A agonists are believed to produce infra-additive effects on locomotor activity in 
rats.[49] 5-HT1A and 5-HT2A receptors are also known to produce opposing effects on 
neuronal excitability[50,51] and body temperature.[52,53] Given the antagonistic 
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relationship between these two receptors, it is not surprising that 5-HT1A activation by 
indoleamine hallucinogens would modulate or attenuate their ability to induce the 
HTR.  However, as far as the authors are aware, LSM-775 is the only indoleamine 
identified to date that fails to elicit the HTR, presumably due to 5-HT1A agonist effects. 
Indeed, indoleamine hallucinogens such as 5-methoxy-N,N-dimethyltryptamine (5-
MeO-DMT) and LSD induce a robust HTR despite acting as potent 5-HT1A receptor 
agonists.[30,54]  
 
Although this is one of the first studies to find that a mixed 5-HT1A/2A agonist fails to 
induce the HTR, similar findings have been reported for certain mixed 5-HT2A/2C 
agonists.  According to a report by Vickers et al.,[55] the 5-HT2 agonist Ro 60-0175 
does not produce the HTR in rats unless administered in combination with the 
selective 5-HT2C antagonist SB-242,084. Similarly, lorcaserin, a 5-HT2 agonist with 
moderate selectivity for 5-HT2C versus 5-HT2A receptors, only induces the HTR in the 
presence of SB-242,084.[56] These findings indicate that 5-HT2C activation can block 
HTR expression. The present results demonstrate that 5-HT1A activation can produce 
similar effects on the HTR. 
 
LSM-775 has been distributed by online vendors as an NPS. According to reports on 
Internet discussion forums and websites, 1 mg LSM-775 mimics the effects produced 
by low doses of LSD, but also induces considerable nausea and feelings of lethargy 
and sedation (e.g.[57]). Similarly, when tested in preliminary clinical trials, LSM-775 
was only capable of producing a weak psychedelic response, similar to low or 
threshold doses of LSD. Based on the present results, it is tempting to speculate that 
the ability of LSM-775 to induce hallucinogenic effects via 5-HT2A activation is limited 
or counteracted by its effects on 5-HT1A receptors. There is some precedent in the 
literature for this type of modulatory interaction: pretreatment with the mixed 5-
HT1A/β-adrenergic antagonist pindolol reportedly produces a significant enhancement 
of the subjective response to N,N-dimethyltryptamine (DMT) in human volunteers, 
indicating the psychedelic effects of DMT are blunted by 5-HT1A activation.
[58] 
Additionally, pretreatment with the 5-HT1A agonist buspirone (20 mg p.o.) markedly 
attenuates the visual effects of psilocybin in human volunteers.[59] Although buspirone 
failed to completely block the hallucinogenic effects of psilocybin, the limited 
inhibition is not necessarily surprising because buspirone is a low efficacy 5-HT1A 
partial agonist.[60] The level of 5-HT1A activation produced by buspirone may not be 
sufficient to completely counteract the stimulation of 5-HT2A receptors by psilocin (the 
active metabolite of psilocybin).  Another consideration is that psilocin acts as a 5-
HT1A agonist.
[61] If 5-HT1A activation by psilocin buffers its hallucinogenic effects 
similar to DMT[58] then competition between psilocin and a weaker partial agonist 
such as buspirone would limit attenuation of the hallucinogenic response. 
 
One caveat is that WAY-100,635 may only have limited selectivity for 5-HT1A 
receptors.  For example, WAY-100,635 acts as an agonist at dopamine D4 
receptors.[62,63] Although several studies have shown that WAY-100,635 has at least 
100-fold selectivity for 5-HT1A vs. D4 receptors,
[62,64,65] another report indicates that 
the difference in affinities may be closer to 10-fold.[63] WAY-100,635 is capable of 
producing D4 receptor-mediated behavioral effects in rats when tested at relatively 
high doses.[66] Nevertheless, it is difficult to conceptualize how D4 activation by WAY-
Page 13 of 29
http://mc.manuscriptcentral.com/dta
Drug Testing and Analysis
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 13
100,635 could be responsible for the behavioral interaction with LSM-775.  D4 
receptor agonists such as apomorphine do not induce the HTR;[46,67] in fact, 
apomorphine actually attenuates the HTR induced by 5-HT2A agonists.
[68,69] 
 
WAY-100,635 also has moderately high affinity for α1 adrenergic receptor subtypes 
(α1A Ki = 19 nM, α1B Ki = 66 nM, α1D Ki = 4.6 nM),
[70] but again this interaction is 
unlikely to play a role in the present results.  Pretreatment with the α1 agonist 
cirazoline does not alter the HTR induced by the 5-HT2A agonist DOI.
[46] By contrast, 
the α1 antagonist prazosin produces significant inhibition of the HTR induced by 
DOI,[46,71] 5-MeO-DMT,[72,73] and quipazine.[74] Likewise, the α1 antagonist 
phenoxybenzamine attenuates the HTR induced by LSD and quipazine.[75] It has not 
been established whether WAY-100,635 acts as an agonist or an antagonist at α1 
subtypes, but based on the aforementioned findings, it is not likely that activation or 
blockade of α1 receptors would enhance the ability of LSM-775 to provoke head 
twitches. 
  
Conclusion 
 
Although the subjective effects of LSM-775 in humans have not been fully 
characterized, LSM-775 does not appear to be capable of producing more than a 
threshold psychedelic response.  Regardless of the dose tested, the effects of LSM-
775 approximated those induced by low doses of LSD.  Based on the results of our 
in vitro and in vivo studies, it was concluded that 5-HT1A receptor activation by LSM-
775 suppresses its 5-HT2A-mediated behavioral responses. Because the psychedelic 
effects of serotonergic hallucinogens are mediated by 5-HT2A receptors, one potential 
explanation for the relative inactivity of LSM-775 in humans is that its effects on the 
5-HT1A receptor may also mask its ability to produce hallucinogenic effects.  Although 
there is some precedent in the literature for this type of modulatory interaction, 
clinical trials are required to determine whether 5-HT1A agonism is responsible for the 
weak psychedelic response to LSM-775. 
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Figure 1. Derivatives of lysergide (LSD) that appeared on the new psychoactive substances market.  
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Figure 2. Electron ionization mass spectrum, gas chromatography retention time and Kovats retention index 
recorded for LSM-775 and its minor isomer.  
 
288x418mm (300 x 300 DPI)  
 
 
Page 21 of 29
http://mc.manuscriptcentral.com/dta
Drug Testing and Analysis
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
  
 
 
GC-solid state-IR spectrum of LSM-775. Top: entire scan range. Bottom: partial scan range.  
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Quadrupole time of flight tandem mass spectrum (ESI-QTOF-MS/MS) recorded for LSM-775. B–E: in-source 
CID spectra under single quadrupole mass spectrometry conditions. F: HPLC-Q-MS trace using the m/z value 
of the protonated molecule for selected ion monitoring (SIM). G: HPLC diode array analysis.  
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Figure 5. A: Crystal structure data obtained for LSM-775 hemitartrate following recrystallization with ethanol 
and water. B: Solvent/anion unit formed a central scaffold around which three molecules of LSM-775 were 
arranged.  
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Figure 6. A: LSM-775 did not significantly increase head twitch response (HTR) counts over baseline levels. 
B: LSM-775 produced a robust increase in HTR counts in mice pretreated with 1 mg/kg of the 5-HT1A 
antagonist WAY-100,635.  Data are presented as group means ± SEM for the entire 30-min test session. 
*p<0.05, **p<0.01, significant differences from the vehicle control group (Tukey’s test).  
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Figure 7. LSM-775 induced the head twitch response (HTR) in mice pretreated with the 5-HT1A antagonist 
WAY-100,635 but not in mice pretreated with vehicle.  Data are presented as group means ± SEM for the 
entire 30-min test session. *p<0.001, significant differences between groups (Tukey’s test).  
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Table 1. 
1
H and 
13
C NMR data for LSM-775 hemitartrate in d6-DMSO at 
600 / 150 MHz 
 
No. 
13
C [δ / ppm] 
1
H [δ / ppm] 
1 – 10.74 (s, 1H) 
2 119.39 7.04 (t, J = 2.0 Hz,1H)
 a
 
3 108.53 – 
4 26.42 3.51 (dd, J = 14.4, 5.4 Hz, 4β-H, 1H) 
b
  
2.57–2.52 (m, 4α-H, 1H) 
c
 
5 62.66 3.19–3.12 (m, 5β-H, 1H) 
6 – – 
7 54.98 3.05 (dd, J = 11.3, 4.8 Hz, 7α-H, 1H) 
2.71–2.67 (m, 7β-H, 1H) 
8 38.30 3.98–3.94 (m, 8α-H, 1H) 
9 119.19 6.30 (s, 1H) 
10 134.82 – 
11 126.95 – 
12 111.19 7.10–7.07 (m, 1H)
 d
 
13 122.30 7.10–7.07 (t, J = 7.2 Hz, 1H)
 e
 
14 109.94 7.20 (dd, J = 7.4, 0.9 Hz, 1H) 
15 133.83 – 
16 125.77 – 
17 43.06 2.54 (s, 3H) 
f
 
18 169.94 – 
19 – – 
20 – – 
21 45.74 3.67–3.57 (m, 2H)
 g
 
21 41.71 3.53–3.49 (m, 2H) 
h
  
22 66.30 3.68–3.57 (m, 2H)
 i
 
22 66.11 3.68–3.57 (m, 2H)
 i
 
TA 
j
 71.95 4.21 (s, 1H) 
TA
 j
 173.44 – 
a 
Part of multiplet between 7.10–7.05 ppm 
 
b 
Overlapping with 1 x 21-CH2 (2H) 
 
c
 Overlapping with 17-CH3 (3H) 
 
d 
Overlapping with H-2 and H-13 (2H) 
 
e 
Overlapping with H-2 and H-12 (2H) 
 
f 
Overlapping with 4α-H (1H) 
 
g 
Overlapping with 2 x 22-CH2 (4H) 
 
h 
Overlapping with 4β-H (1H) 
1
2
3
4
15
14
13
12
5
678
9
10
11
16
NH
N
O
H
H
H
H
Hα α
β
α
β
19
17
N
20
22
21
18
21
22
O
Hβ
23
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i 
Overlapping with 1 x 21-CH2 (2H) 
 
j 
TA: tartaric acid 
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Table 2.  Binding affinities of LSM-775 and reference 
compounds for cloned 5-HT1A and 5-HT2A receptors. 
 Ki (nM) 
a,b 
 Human 5-HT1A Human 5-HT2A 
Compound [3H]8-OH-DPAT [3H]ketanserin 
LSM-775 31.0 ± 7.4 (3) 29.5 ± 4.1 (4) 
8-OH-DPAT   0.72 ± 0.10 (3) ND c 
Clozapine ND 11.5 ± 3.3 (4) 
a 
Mean ± SEM. 
b 
The number of independent determinations are listed in 
parentheses. 
c 
ND: not determined. 
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Table 3.  Functional activity of LSM-775 and 5-HT at selected serotonin 
receptors. 
 
 
Receptor 
LSM-775 5-HT 
EC50, nM 
(pEC50 ± SEM) 
Emax 
% 5-HT 
EC50, nM 
(pEC50 ± SEM) 
Emax 
% 5-HT 
h5-HT1A 1.03 
(8.99 ± 0.03) 
98 ± 2 0.26 
(9.58 ± 0.03) 
100 
h5-HT2A 4.9 
(8.31 ± 0.07) 
89 ± 2 0.35 
(9.50 ± 0.04) 
100 
m5-HT2A 19 
(7.72 ± 0.04) 
88 ± 1 0.57 
(9.24 ± 0.02) 
100 
h5-HT2B 26 
(7.58 ± 0.02) 
77 ± 2 0.85 
(9.07 ± 0.02) 
100 
h5-HT2C 230 
(6.64 ± 0.03) 
77 ± 3 0.20 
(9.58 ± 0.03) 
100 
Data were acquired with HEK293 cells expressing either human 5-HT1A 
(h5-HT1A), human 5-HT2A (h5-HT2A), mouse 5-HT2A (m5-HT2A), human 5-
HT2B (h5-HT2B), or human 5-HT2C INI (h5-HT2C) receptors.  Data represent 
EC50 and Emax means and standard error of the mean (SEM) from three 
independent experiments performed in triplicate.  Emax is defined as percent 
5-HT maximum response. 
 
Page 30 of 29
http://mc.manuscriptcentral.com/dta
Drug Testing and Analysis
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
